Literature DB >> 8638113

HIV-1 Langerhans' cell tropism associated with heterosexual transmission of HIV.

L E Soto-Ramirez1, B Renjifo, M F McLane, R Marlink, C O'Hara, R Sutthent, C Wasi, P Vithayasai, V Vithayasai, C Apichartpiyakul, P Auewarakul, V Peña Cruz, D S Chui, R Osathanondh, K Mayer, T H Lee, M Essex.   

Abstract

Heterosexual transmission by vaginal intercourse accounts for most transmission of human immunodeficiency virus-type 1 (HIV-1) in Africa and Asia but is less important in the HIV-1 epidemics of the United States and Western Europe. Epithelial Langerhans' cells (LCs) represent a possible source of initial cell contact for vaginal infection. Fifteen primary isolates of HIV-1 from U.S. homosexuals and 18 HIV-1 isolates from Thailand heterosexuals were evaluated for growth in LCs of U.S. origin. All the viruses from the Thai heterosexuals, which were subtype E, grew more efficiently in the LCs than any of the viruses from the U.S. homosexuals, which are subtype B. These results suggest that LC tropism is associated with the efficiency of heterosexual transmission of HIV.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8638113     DOI: 10.1126/science.271.5253.1291

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  55 in total

Review 1.  Global impact of human immunodeficiency virus and AIDS.

Authors:  H D Gayle; G L Hill
Journal:  Clin Microbiol Rev       Date:  2001-04       Impact factor: 26.132

2.  A distinctive clade B HIV type 1 is heterosexually transmitted in Trinidad and Tobago.

Authors:  F R Cleghorn; N Jack; J K Carr; J Edwards; B Mahabir; A Sill; C B McDanal; S M Connolly; D Goodman; R Q Bennetts; T R O'Brien; K J Weinhold; C Bartholomew; W A Blattner; M L Greenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2000-09-12       Impact factor: 11.205

3.  Simian-human immunodeficiency virus containing a human immunodeficiency virus type 1 subtype-E envelope gene: persistent infection, CD4(+) T-cell depletion, and mucosal membrane transmission in macaques.

Authors:  S Himathongkham; N S Halpin; J Li; M W Stout; C J Miller; P A Luciw
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

4.  Sequestration of TT virus of restricted genotypes in peripheral blood mononuclear cells.

Authors:  H Okamoto; M Takahashi; N Kato; M Fukuda; A Tawara; S Fukuda; T Tanaka; Y Miyakawa; M Mayumi
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

5.  Predicting the level of vaccine-induced cross-immunity necessary to eliminate HIV epidemics composed of multiple subtypes.

Authors:  David J Gerberry; Sally Blower
Journal:  AIDS       Date:  2010-06-19       Impact factor: 4.177

6.  Postentry restriction to human immunodeficiency virus-based vector transduction in human monocytes.

Authors:  S Neil; F Martin; Y Ikeda; M Collins
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

Review 7.  Use of assisted reproductive technology to reduce the risk of transmission of HIV in discordant couples wishing to have their own children where the male partner is seropositive with an undetectable viral load.

Authors:  H W G Baker; A Mijch; S Garland; S Crowe; M Dunne; D Edgar; G Clarke; P Foster; J Blood
Journal:  J Med Ethics       Date:  2003-12       Impact factor: 2.903

8.  Divergent transcriptional regulation among expanding human immunodeficiency virus type 1 subtypes.

Authors:  M A Montano; V A Novitsky; J T Blackard; N L Cho; D A Katzenstein; M Essex
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

Review 9.  Weighing the Evidence of Efficacy of Oral PrEP for HIV Prevention in Women in Southern Africa.

Authors:  Holly Janes; Lawrence Corey; Gita Ramjee; Lindsay N Carpp; Carl Lombard; Myron S Cohen; Peter B Gilbert; Glenda E Gray
Journal:  AIDS Res Hum Retroviruses       Date:  2018-06-19       Impact factor: 2.205

Review 10.  HIV/AIDS epidemiology, pathogenesis, prevention, and treatment.

Authors:  Viviana Simon; David D Ho; Quarraisha Abdool Karim
Journal:  Lancet       Date:  2006-08-05       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.